中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

40 records (took 0.026 seconds)

    신규한 1-[1-(3,4-디알콕시페닐)-알킬]-1Ｈ-피라졸 화합물,이의 제조방법 및 이를 포함하는 약제학적 조성물
    2.
    发明公开
    신규한 1-[1-(3,4-디알콕시페닐)-알킬]-1Ｈ-피라졸 화합물,이의 제조방법 및 이를 포함하는 약제학적 조성물 失效
    1- [1-（3,4-二甲氧基苯基） - 乙基] -1H-吡唑化合物，其制备方法和包含其的药物组合物

    公开(公告)号：KR1020080065722A

    公开(公告)日：2008-07-15

    申请号：KR1020070002715

    申请日：2007-01-10

    Applicant: 한국화학연구원

    Inventor： 전동주 ,  노재성 ,  송종환 ,  이계형 ,  김익연 ,  박창민 ,  소원영 ,  이지선 ,  김은주 ,  강남숙 ,  천혜경 ,  조영식 ,  송진숙 ,  배명애 ,  김지현 ,  조중명 ,  노성구 ,  현영란 ,  이철순 ,  이재일 ,  유성은

    IPC: C07D231/12 ,  C07D401/04 ,  C07D403/10 ,  C07D413/04

    Abstract: A novel compound is provided to show excellent activity on PDE-4 enzymes and high selectivity on other PDE enzymes, thereby being used as a therapeutic agent of inflammation related diseases, arthritis, atopic dermatitis, leukemia, various cancers and degenerative brain diseases with little side effects. A 1-[1-(3,4-dialkoxyphenyl)-alkyl]-1H-pyrazole compound is represented by a formula(1) and is prepared by reacting a halo-benzyl compound represented by a formula(2) with a pyrazole compound represented by a formula(3). In the formula(1), each R1 and R2 is independently H, linear or branched saturated or unsaturated C1-7 alkyl which may be substituted or unsubstituted by halogen, C3-7 cycloalkyl, (C3-7)cycloalkyl(C1-7)alkyl, aryl or heteroaryl, ar(C1-5)alkyl, or ar(C1-5)alkoxy, or the R1 and R2 may be linked to each other by C1-3 alkylene; each R3, R4 and R5 is independently H, phenyl, pyridinyl, N-oxypyridinyl, linear or branched saturated and unsaturated C1-7 alkyl, C3-7 cycloalkyl, (C3-10)cycloalkyl(C1-7)alkyl, halogen, cyano, nitro, amino, mono- or di(C1-7)alkylamino, mono or di(C1-7)alkylaminocarbonyl, C3-7 cycloalkylamino, 3 to 7-membered saturated or unsaturated hetero-ring including O, N or S, guanidinyl, ureido, benzyl, benzyloxy, formyl, C1-7 alkanoyl, C1-7 alkoxy, (C1-7)alkoxy(C1-7)alkyl, hydroxy(C1-7)alkyl, carboxyl, or (C1-7)alkoxycarbonyl; R6 is linear or branched saturated and unsaturated C1-7 alkyl, C3-7 cycloalkyl, (C3-10)cycloalkyl(C1-7)alkyl, phenyl, phenoxy, benzyl, benzyloxy, C1-7 alkoxy, or (C1-7)alkoxy(C1-7)alkyl. A pharmaceutical composition for treating or preventing diseases related to airway inflammation, arthritis, atopic dermatitis, leukemia, cancer or degenerative brain diseases comprises the 1-[1-(3,4-dialkoxyphenyl)-alkyl]-1H-pyrazole derivative as an effective ingredient.

    Abstract translation: 提供了一种新型化合物，以显示对PDE-4酶的优异活性和对其他PDE酶的高选择性，从而被用作炎症相关疾病，关节炎，特应性皮炎，白血病，各种癌症和退行性脑病的治疗剂 效果。 1-（1-（3,4-二烷氧基苯基） - 烷基] -1H-吡唑化合物由式（1）表示，通过式（2）表示的卤代苄基化合物与吡唑化合物 由公式（3）表示。 在式（1）中，每个R 1和R 2独立地为H，可被卤素取代或未取代的直链或支链饱和或不饱和C 1-7烷基，C 3-7环烷基，（C 3-7）环烷基（C 1-7） 烷基，芳基或杂芳基，芳（C 1-5）烷基或芳（C 1-5）烷氧基，或者R 1和R 2可以被C 1-3亚烷基相互连接; 每个R 3，R 4和R 5独立地为H，苯基，吡啶基，N-氧代吡啶基，直链或支链饱和和不饱和C 1-7烷基，C 3-7环烷基，（C 3-10）环烷基（C 1-7）烷基，卤素，氰基 ，硝基，氨基，单或二（C1-7）烷基氨基，单或二（C1-7）烷基氨基羰基，C3-7环烷基氨基，3至7元饱和或不饱和杂环，包括O，N或S，胍基 （C 1-7）烷基，羟基（C 1-7）烷基，羧基或（C 1-7）烷氧基羰基;（C 1-7）烷氧基， R6是直链或支链饱和和不饱和的C1-7烷基，C3-7环烷基，（C3-10）环烷基（C1-7）烷基，苯基，苯氧基，苄基，苄氧基，C1-7烷氧基或（C1-7） 烷氧基（C 1-7）烷基。 用于治疗或预防与气道炎症，关节炎，特应性皮炎，白血病，癌症或退行性脑疾病相关的疾病的药物组合物包括1- [1-（3,4-二烷氧基苯基） - 烷基] -1H-吡唑衍生物作为有效的 成分。

    7-(3,4-디알콕시페닐)-피라졸로[1,5-ａ]피리미딘 화합물을포함하는 관절염, 아토피 피부염, 백혈병을 포함한 암 및알쯔하이머, 우울증 또는 기억력 감소 등의 뇌질환의 치료및 예방을 위한 약제학적 조성물
    3.
    发明授权
    7-(3,4-디알콕시페닐)-피라졸로[1,5-ａ]피리미딘 화합물을포함하는 관절염, 아토피 피부염, 백혈병을 포함한 암 및알쯔하이머, 우울증 또는 기억력 감소 등의 뇌질환의 치료및 예방을 위한 약제학적 조성물 失效
    7-（3,4-디알콕시페닐） - 피라졸로[1,5-α]피리미딘화합물을포함하는관절염，아토피피부염，백혈병을포함한암및알쯔하이머，우울증또는기억력감소등의뇌질환의치료및 예방을위약제제학적조성

    公开(公告)号：KR100753017B1

    公开(公告)日：2007-08-30

    申请号：KR1020060046860

    申请日：2006-05-25

    Applicant: 한국화학연구원

    Inventor： 노재성 ,  전동주 ,  송종환 ,  이계형 ,  박창민 ,  소원영 ,  강남숙 ,  홍석주 ,  천혜경 ,  조영식 ,  김기영 ,  배명애 ,  송진숙 ,  노성구 ,  현영란 ,  이운영 ,  김용은 ,  강봉균 ,  이혜련 ,  유성은

    IPC: A61K31/437 ,  A61P35/00

    Abstract: A pharmaceutical composition for treating or preventing arthritis, atopic dermatitis, tumor and degenerative brain diseases comprising 7-(3,4-Dialkoxyphenyl)-pyrazolo[1,5-a]pyrimidine compounds is provided to inhibit activity of PDE-4(phosphodiesterase-4) and reduce side effects such as vomiting by reducing HARBS(high-affinity rolipram binding sites) affinity. The pharmaceutical composition for treating or preventing arthritis, atopic dermatitis, tumor and degenerative brain diseases comprises 7-(3,4-Dialkoxyphenyl)-pyrazolo[1,5-a]pyrimidine compounds represented by the formula(1), wherein R1 and R2 are independently hydrogen atom, linear or branched saturated or unsaturated (C1-C7)alkyl, linear or branched saturated or unsaturated (C1-C7)alkyl containing halogen atom, (C3-C7)cycloalkyl, 3-membered to 7-membered heterocycloalkyl containing oxygen, nitrogen or sulfur in a hetero aromatic ring, (C4-C10)cycloalkyl(C1-C7)alkyl, 3-membered to 7-membered heterocycloalkyl(C1-C7)alkyl containing oxygen, nitrogen or sulfur in a hetero ring, phenyl, benzyl or allyl group; R3 is hydrogen atom, halogen atom, formyl, linear or branched and saturated or unsaturated (C1-C7)alkyl, (C1-C7)alkylketone, (C1-C7)alkoxy, (C1-C7)alkoxy (C1-C7)alkyl, hydroxy(C1-C7)alkyl group, carboxylic acid, carboxyl(C1-C7)alkylester, carboxyl(C1-C7)alkylamide, amino, or mono or di(C1-C7)alkylaminocarbonyl; and R4 is hydrogen atom, formyl, linear or branched saturated or unsaturated (C1-C7)alkyl, (C3-C7)cycloalkyl, (C1-C7)alkoxy, (C1-C7)alkoxy (C1-C7)alkyl, hydroxy(C1-C7)alkyl ketone, (C1-C10)alkylcarboxylic acid, carboxyl(C1-C10)alkylester, carboxyl(C1-C10)alkylamide, amino, mono or di(C1-C7)alkylamino, mono or di(C1-C7)alkylaminocarbonyl, (C3-C7)cycloalkylamine, morpholine, morpholine oxide, piperidine, piperazine, piperazine oxide or aryl group.

    Abstract translation: 用于治疗或预防关节炎，特应性皮炎，肿瘤和退行性脑疾病，其包括7-（3,4-二烷氧基） - 吡唑并提供[1,5-a]嘧啶化合物抑制PDE-4的活性（phosphodiesterase-的药物组合物 4）并通过减少HARBS（高亲和力咯利普兰结合位点）亲和力来减少副作用，例如呕吐。 用于治疗或预防关节炎，特应性皮炎，肿瘤和退行性脑疾病的药物组合物包含7-（3,4-二烷氧基） - 吡唑并[1,5-a]嘧啶化合物由式（1）表示，其中R1和R2 （C 1 -C 7）烷基，含有卤素原子的直链或支链饱和或不饱和（C 1 -C 7）烷基，（C 3 -C 7）环烷基，含有3至7元杂环烷基的3元至7元杂环烷基 （C4-C10）环烷基（C1-C7）烷基，在杂环中含有氧，氮或硫的3元至7元杂环烷基（C1-C7）烷基，苯基 ，苄基或烯丙基; （C 1 -C 7）烷基，（C 1 -C 7）烷氧基，（C 1 -C 7）烷氧基（C 1 -C 7）烷基，（C 1 -C 7）烷氧基， （C 1 -C 7）烷基，羧酸，羧基（C 1 -C 7）烷基酯，羧基（C 1 -C 7）烷基酰胺，氨基或单或二（C 1 -C 7）烷基氨基羰基; （C 1 -C 7）烷基，（C 3 -C 7）环烷基，（C 1 -C 7）烷氧基，（C 1 -C 7）烷氧基（C 1 -C 7）烷基，羟基（C 1 -C 7）烷基， C1-C7）烷基酮，（C1-C10）烷基羧酸，羧基（C1-C10）烷基酯，羧基（C1-C10）烷基酰胺，氨基，单或二（C1-C7）烷基氨基，单或二（C1-C7 ）烷基氨基羰基，（C3-C7）环烷基胺，吗啉，氧化吗啉，哌啶，哌嗪，哌嗪氧化物或芳基。

    믹소첼린-에이를 유효성분으로 하는 항산화 및 항암용약학 조성물
    6.
    发明公开
    믹소첼린-에이를 유효성분으로 하는 항산화 및 항암용약학 조성물 失效
    含有MYXOCHELIN-A作为有效成分的抗氧化剂和抗癌药物组合物

    公开(公告)号：KR1020030005787A

    公开(公告)日：2003-01-23

    申请号：KR1020010041239

    申请日：2001-07-10

    Applicant: 한국화학연구원

    Inventor： 안종웅 ,  이호현 ,  노재성 ,  이계형 ,  이정옥 ,  최상운 ,  권중호

    IPC: A61K31/165

    Abstract: PURPOSE: A pharmaceutical composition containing myxochelin-A which exhibits excellent anticancer activity against human cancer cells, together with excellent antioxidant activity as a main component is provided which can be effectively used as an effective antioxidant and anticancer agent. CONSTITUTION: The pharmaceutical composition contains myxochelin-A of formula 1 obtained by being separated from myxobacteria or being chemically synthesized or semisynthesized. The myxochelin-A is purely separated by the steps of: separating a biomass and absorption resin by culturing Angiococcus disciformis strains as myxobacteria in the presence of absorption resin and centrifuging a culture solution; adding an organic solvent, preferably a mixed solvent of acetone and methanol; extracting and filtering to remove the biomass and absorption resin; preparing an active fraction by concentrating the filtrate under reduced pressure and extracting a crude extract in an organic solvent; and successively performing silica gel liquid chromatography and recycling preparative HPLC.

    Abstract translation: 目的：提供能够有效地用作有效的抗氧化剂和抗癌剂的含有对人类癌细胞具有优异抗癌活性的粘液素-A的药物组合物，以及优异的抗氧化活性为主要成分。 构成：药物组合物含有通过与粘液细菌分离或化学合成或半合成获得的式1的粘液素-A。 通过以下步骤纯化粘液素-A：通过在吸收树脂存在下培养球状球形细菌菌株作为粘液细菌分离生物质和吸收树脂并离心培养液; 加入有机溶剂，优选丙酮和甲醇的混合溶剂; 提取和过滤除去生物质和吸收树脂; 通过减压浓缩滤液并在有机溶剂中萃取粗提取物制备活性级分; 并依次进行硅胶液相色谱和再循环制备型HPLC。

    5'-(히드록시-보호된)-5-(치환 또는 비치환)-2,3'-안히드로-2'-데옥시우리딘 화합물의 제조방법
    7.
    发明公开
    5'-(히드록시-보호된)-5-(치환 또는 비치환)-2,3'-안히드로-2'-데옥시우리딘 화합물의 제조방법 无效
    制备5-（羟基保护的）-5-（取代或未取代的）2,3-羟基-2-脱氧INE啶化合物的方法

    公开(公告)号：KR1020010056060A

    公开(公告)日：2001-07-04

    申请号：KR1019990057477

    申请日：1999-12-14

    Applicant: 한국화학연구원

    Inventor： 노재성 ,  신동성 ,  안미자

    IPC: C07D498/12

    Abstract: PURPOSE: Provided is a method for manufacturing 5-(hydroxy-protected)-5-(substituted or unsubstituted)2,3-anhydro-2-deoxyuridine compound in a high yield which is useful as an intermediate of a compound useful in treating acquired immune deficiency syndrome (AIDS). CONSTITUTION: The method for manufacturing 5-(hydroxy-protected)-5-(substituted or unsubstituted)2,3-anhydro-2-deoxyuridine compound is characterized by the next step of: reacting 5-(hydroxy protected)-5-(substituted or unsubstituted)-2-deoxyuridine of the formula (4) with 1,1-sulfonyldiimidazole of the formula (3) in the presence of base and polar or nonpolar organic solvent at 0-150 deg.C, preferably 25-90 deg.C. Optionally, 1.2-2.0 equivalents of the compound (3) are added per 1 equivalent of the compound (4) to improve its yield more.

    Abstract translation: 目的：提供以高产率制备5-（羟基保护的）-5-（取代或未取代）2,3-脱水-2-脱氧尿苷化合物的方法，其可用作用于治疗所获得的化合物的中间体 免疫缺陷综合征（AIDS）。 构成：5-（羟基保护）-5-（取代或未取代）2,3-脱水-2-脱氧尿苷化合物的制备方法的特征在于下列步骤：使5-（羟基保护的）-5-（ 取代或未取代的）式（4）的脱氧尿苷与式（3）的1,1-磺酰基二咪唑在碱和极性或非极性有机溶剂存在下在0-150℃，优选25-90度 。C。 任选地，每1当量化合物（4）加入1.2-2.0当量的化合物（3），以提高其产率。

    7-(3′,4′-디알콕시페닐)-[1,2,4]트리아졸로[1,5-ａ]피리미딘 화합물, 이의 제조방법 및 이를 포함하는 천식 및만성폐쇄성 폐질환을 포함한 염증관련 질환, 관절염,아토피 피부염, 암 및 뇌질환의 치료 및 예방을 위한약제학적 조성물
    10.
    发明授权
    7-(3′,4′-디알콕시페닐)-[1,2,4]트리아졸로[1,5-ａ]피리미딘 화합물, 이의 제조방법 및 이를 포함하는 천식 및만성폐쇄성 폐질환을 포함한 염증관련 질환, 관절염,아토피 피부염, 암 및 뇌질환의 치료 및 예방을 위한약제학적 조성물 失效
    7-（3'，4'-二烷氧基苯基） - [1,2,4] - 三唑并[1,5-A]吡啶化合物，其制备方法和药物组合物，用于治疗或预防哮喘，慢性阻塞性肺动脉疾病， ARTHRITIS，ATOPIC DERMATITIS，TUMOR AND DEGENERATIVE BRAIN DISEASES COMPATH THE SAME

    公开(公告)号：KR100844125B1

    公开(公告)日：2008-07-04

    申请号：KR1020070028620

    申请日：2007-03-23

    Applicant: 한국화학연구원

    Inventor： 전동주 ,  노재성 ,  송종환 ,  이계형 ,  김익연 ,  박창민 ,  천혜경 ,  조영식 ,  송진숙 ,  배명애 ,  유성은

    IPC: C07D487/04 ,  A61K31/519

    CPC classification number: C07D487/04

    Abstract: A 7-(3',4'-dialkoxyphenyl)-[1,2,4]-triazolo[1,5-a]pyrimidine compound is provided to show excellent activity on PDE-4 enzymes and high selectivity on other PDE enzymes and improve vomiting related side effects, which is one most serious problem of the PDE-4 inhibitors, thereby being used as a therapeutic agent of asthma and chronic obstructive pulmonary diseases, arthritis, atopic dermatitis, leukemia, cancer and brain diseases. A 7-(3',4'-dialkoxyphenyl)-[1,2,4]-triazolo[1,5-a]pyrimidine compound is represented by a formula(1) and is prepared by reacting 3-amino-triazole compound represented by a formula(4) with 3-(dimethylamino)-1-(3,4-dialkoxyphenyl)prophenone compound represented by a formula(5) or 3-(3,4-dialkoxyphenyl)3-oxopropionealdehyde compound represented by a formula(6) in the presence of acetic acid. In the formulae, each R1 and R2 is independently H, linear or branched saturated or unsaturated C1-7 alkyl, linear or branched saturated or unsaturated C1-7 alkyl including O, N or S, C3-7 cycloalkyl, C3-7 cycloalkyl including O, N or S, (C3-7)cycloalkyl(C1-7)alkyl, 3 to 7-membered saturated or unsaturated heterocycloalkyl including O, N, or S in a heterocycle, phenyl or benzyl, or R1 and R2 may be linked to each other by C1-3 alkylene or C1-3 alkylene including halogen; R3 is aryl selected from groups(1) to (4). A pharmaceutical composition for treating or preventing diseases related to bronchial inflammation such as asthma and chronic obstructive pulmonary disease, arthritis, atopic dermatitis, leukemia, cancer and brain diseases such as Alzheimer's disease, depression and memory decrease comprises the 7-(3',4'-dialkoxyphenyl)-[1,2,4]-triazolo[1,5-a]pyrimidine compound or a pharmaceutically acceptable carrier as an effective ingredient.

    Abstract translation: 提供7-（3'，4'-二烷氧基苯基） - [1,2,4] - 三唑并[1,5-a]嘧啶化合物以显示对PDE-4酶的优异活性和对其它PDE酶的高选择性， 改善呕吐相关的副作用，这是PDE-4抑制剂的一个最严重的问题，从而被用作哮喘和慢性阻塞性肺疾病，关节炎，特应性皮炎，白血病，癌症和脑疾病的治疗剂。 7-（3'，4'-二烷氧基苯基） - [1,2,4] - 三唑并[1,5-a]嘧啶化合物由式（1）表示，并通过3-氨基 - 三唑化合物 由式（4）与由式（5）表示的3-（二甲基氨基）-1-（3,4-二烷氧基苯基）丙烯酮化合物或由式（5）表示的3-（3,4-二烷氧基苯基）3-氧代丙醛化合物 （6）在乙酸存在下。 在该式中，每个R 1和R 2独立地为H，直链或支链饱和或不饱和的C 1-7烷基，包括O，N或S，C 3-7环烷基，C 3-7环烷基的直链或支链饱和或不饱和C 1-7烷基，包括 O，N或S，（C 3-7）环烷基（C 1-7）烷基，在杂环中包括O，N或S的3至7元饱和或不饱和杂环烷基，苯基或苄基，或R 1和R 2可以相连 通过C1-3亚烷基或包括卤素的C1-3亚烷基; R3是选自（1）〜（4）的芳基。 用于治疗或预防与哮喘和慢性阻塞性肺病，关节炎，特应性皮炎，白血病，癌症和脑疾病如阿尔茨海默病，抑郁和记忆减退等支气管炎有关的疾病的药物组合物包括7-（3'，4 '二烷氧基苯基） - [1,2,4] - 三唑并[1,5-a]嘧啶化合物或药学上可接受的载体作为有效成分。

Patent Agency Ranking